
    
      The pharmacokinetics of a new formulation of taxane (liposomal paclitaxel) has never been
      studied in Chinese cancer patients. This clinical trial is designed to find out the
      pharmacokinetics of liposomal paclitaxel at the dose of 175mg/m2 and whether it has a
      different pharmacokinetic profile to paclitaxel.
    
  